Skip to main content

Qualified laboratory research use only. Not for human or veterinary use, consumption, administration, compounding, diagnosis, or treatment.

RESEARCH USE ONLY
Selank Vespera catalog photography

Research material profile

Selank

Synthetic tuftsin-derived heptapeptide

Selank is a seven-amino-acid peptide derived from the tuftsin sequence. Published mechanistic work has examined GABA-receptor binding and neurotransmission-related gene expression, mostly in laboratory and animal systems.

Identity shorthand
TKPRPGP
Evidence map
Mechanistic and animal-model evidence
Public page scope
Identity and literature context; no purchase offer
Commerce accessQualified laboratory buyers only

Pricing, availability, ordering, cart, and checkout remain inside the reviewed qualified-access portal.

Qualified catalog access

Plain-language identity

What Selank is

Selank is a seven-amino-acid peptide derived from the tuftsin sequence. Published mechanistic work has examined GABA-receptor binding and neurotransmission-related gene expression, mostly in laboratory and animal systems.

Research class
Synthetic tuftsin-derived heptapeptide
Sequence / identity shorthand
TKPRPGP
Evidence map
Mechanistic and animal-model evidence
Identity boundary

The literature may refer to Selank free base, acetate, or other characterized preparations. Counter-ion and lot identity should be kept explicit in any research record.

What researchers examine

  • GABA-receptor binding and proposed allosteric modulation in membrane preparations.
  • Short-term neurotransmission-related gene-expression changes in rat frontal cortex.
  • How molecular form, model system, and regional literature affect interpretation.

How to read the evidence

  • A 2016 rat study measured time-dependent expression changes in a panel of neurotransmission-related genes after Selank or GABA exposure.
  • A 2018 receptor-binding study described concentration-dependent modulation of radiolabeled GABA binding.
  • Mechanistic similarity does not establish equivalence to a medicine, a clinical outcome, or safety for personal use.

What this evidence does not establish

  • Much of the accessible literature is mechanistic, animal-based, or regionally published; broad clinical conclusions are not warranted.
  • FDA identifies limited safety information and immunogenicity and peptide-impurity concerns for compounded drugs containing Selank acetate.
  • This catalog material is not a drug, supplement, or product for administration.

Documentation checklist

  • Record sequence, counter-ion or salt form, SKU, lot, nominal quantity, and analytical method.
  • Treat gene-expression and receptor-binding results as model-specific measurements.
  • Keep identity, purity, quantity, endotoxin, and sterility questions analytically separate.

Primary and official sources

Links are provided for source review. A citation is not an endorsement of nonresearch use.

  1. Volkova et al. — Selank and neurotransmission-related gene expression (2016)Rat frontal-cortex gene-expression study.
  2. Vyunova et al. — Selank and GABA-receptor binding (2018)Radioligand receptor study.
  3. FDA — bulk substances that may present significant safety risksRegulatory context for compounded drugs containing Selank acetate.
Research use only. This profile contains identity and literature context only. It provides no dosing, administration, reconstitution, diagnosis, treatment, or personal-use guidance.